Impaired oxidation of debrisoquine in patients with perhexiline neuropathy
about
Adverse drug reactions.Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugsEvidence-based selection of training compounds for use in the mechanism-based integrated prediction of drug-induced liver injury in manPresent and future pharmacotherapeutic agents in heart failure: an evolving paradigmFlecainide induced peripheral neuropathySevere ocular side effects of perhexilene maleate: case reportEnzymatic oxidation of xenobiotic chemicals.Genetic polymorphisms of human N-acetyltransferase, cytochrome P450, glutathione-S-transferase, and epoxide hydrolase enzymes: relevance to xenobiotic metabolism and toxicity.Perhexiline maleate in the treatment of fibrodysplasia ossificans progressiva: an open-labeled clinical trial.Antibodies against human cytochrome P-450db1 in autoimmune hepatitis type II.Polymorphic hydroxylation of perhexiline maleate in man.The role of CYP2D6 in primary and secondary oxidative metabolism of dextromethorphan: in vitro studies using human liver microsomesGenetically-determined interaction between propafenone and low dose quinidine: role of active metabolites in modulating net drug effect.Extensive oxidative metabolism of dextromethorphan in patients with almitrine neuropathy.Idiosyncratic drug reactions: a mechanistic evaluation of risk factorsDebrisoquine oxidation in an Australian population.Quinidine and the identification of drugs whose elimination is impaired in subjects classified as poor metabolizers of debrisoquine.Assessment of the drug metabolism capacity of the liver.Impaired oxidation of debrisoquine in patients with perhexiline liver injuryAdverse effects from metoprolol are not generally associated with oxidation status.Partial fatty acid oxidation inhibitors for stable angina.Personalizing health care: feasibility and future implications.Pharmacogenetics in drug regulation: promise, potential and pitfalls.Polymorphic hydroxylation of perhexiline in vitro.Concentration-time profile for perhexiline and hydroxyperhexiline in patients at steady stateClinical inhibition of CYP2D6-catalysed metabolism by the antianginal agent perhexiline.Differences in hepatic drug accumulation and enzyme induction after chronic amiodarone feeding of two rat strains: role of the hydroxylator phenotype?Myocardial energy metabolism during ischemia and the mechanisms of metabolic therapies.Mechanistic basis of adverse drug reactions: the perils of inappropriate dose schedules.Genetic aspects of drug disposition and therapeutics.Personalized medicine: is it a pharmacogenetic mirage?Drug metabolism and pharmacogenetics: the British contribution to fields of international significanceMetabolic therapeutics in angina pectoris: history revisited with perhexiline.Steady-state pharmacokinetics of the enantiomers of perhexiline in CYP2D6 poor and extensive metabolizers administered Rac-perhexilineCan pharmacogenetics help rescue drugs withdrawn from the market?Misoprostol does not alter the pharmacokinetics of propranolol.Metabolic therapy for the treatment of ischemic heart disease: reality and expectations.Overview of emerging pharmacotherapy in chronic heart failure.Approaches to deorphanization of human and microbial cytochrome P450 enzymes.Drugs that Affect Cardiac Metabolism: Focus on Perhexiline.
P2860
Q24524192-74459406-3488-4418-A668-A14EE9C65AB9Q24683013-9B5B605C-A1EB-4A9A-B5D3-7CC70A10261EQ28069617-F80240D8-0F9B-4D74-92D5-F88A3720395BQ28077186-B1749489-2FC8-4DD6-B5EC-68479D6C88C9Q28326920-06E5E097-01FC-4FC1-AC32-AA10FE23733CQ28367099-D24DFC31-6D3A-4D34-9115-7659CB514328Q30405933-9379377B-3615-412F-88FF-DABD4BD98811Q33538523-EEBD9C65-05F4-46D7-9B96-2A6A51EBBF75Q33589769-EA2FCE04-67CA-4B3D-A956-0E8D10AB0479Q33665767-2A95C2D3-DCAE-47DC-98D8-FD69A66869A0Q33671047-8FDA9530-73F7-4B18-9A0C-D6223D3A3D6FQ34346292-4FD15B77-9747-4CB9-BC8A-04F123CB78A2Q34397040-38A25830-4D1F-44A0-BCF6-8EB67887BF98Q34397478-9E944BB7-1A4C-4AC6-8230-A1D4DED369D7Q34403403-BF794066-5A37-40D9-8ED3-35D7E60C0721Q34447633-94DAE120-EE06-44BD-9599-B667C163437DQ34448258-EC084080-7BB1-4B3B-BBED-CBCC7BFDA4FFQ34511238-4AADB5F4-E656-4042-B4B3-B0F4EC3A98BBQ34526158-4769DED6-7C15-4B51-BD89-5254C369515CQ34622046-C08012C3-E322-4C8B-813B-ADFE42E6193EQ34628656-EB9678EE-4D9D-4271-BE04-595BA0BF6F97Q34938911-A63F189A-94FA-4AE3-92D6-CD7E886EA6FFQ35038052-248E3BF6-6E2E-4D47-AE8A-01D38003C52CQ35825349-8A796349-CE5B-401C-A41E-9E13A6F767F2Q35825990-F36026BD-1221-4455-B909-DC0F1CE4B27CQ35826004-23FE7921-1D1C-4B50-A955-A510836B32EBQ35888038-0C717DF8-9989-4182-8BF0-1596D7FE5B83Q35892161-813766DE-B6B7-47C7-9E20-7AEEC2181036Q36040772-9DF92062-6326-440B-97B0-75DC11D38DAFQ36244452-E23609DB-EE84-4564-9BA4-BA074F1195DEQ36336007-16FB0DCE-43CC-4885-86E0-B6DBDB243129Q36364455-1DD416FB-D21C-4183-85FA-A27F1A1C4249Q36392401-A264AA87-D4E6-4C93-B347-C40D14E274E2Q36535908-614D1387-3731-4C37-8154-1E07BDE0F69CQ36596713-6466492B-F94F-4F6B-9A59-4D6D6D03E2A3Q36681683-A86723B9-9FF0-429A-A796-BAF6416DAB7DQ37012951-2E3B7A6D-29C6-4343-B8A6-A89EFF90A432Q37552943-D55830E6-0A35-4E1A-9C11-64B025BB2273Q37759731-C9DBF538-FA42-4640-A797-319DAFD1687AQ38815503-3271CE0F-F52F-49CE-9F8D-1F53946560D0
P2860
Impaired oxidation of debrisoquine in patients with perhexiline neuropathy
description
1982 nî lūn-bûn
@nan
1982 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
1982 թվականի հունվարին հրատարակված գիտական հոդված
@hy
1982年の論文
@ja
1982年論文
@yue
1982年論文
@zh-hant
1982年論文
@zh-hk
1982年論文
@zh-mo
1982年論文
@zh-tw
1982年论文
@wuu
name
Impaired oxidation of debrisoquine in patients with perhexiline neuropathy
@ast
Impaired oxidation of debrisoquine in patients with perhexiline neuropathy
@en
Impaired oxidation of debrisoquine in patients with perhexiline neuropathy
@nl
type
label
Impaired oxidation of debrisoquine in patients with perhexiline neuropathy
@ast
Impaired oxidation of debrisoquine in patients with perhexiline neuropathy
@en
Impaired oxidation of debrisoquine in patients with perhexiline neuropathy
@nl
prefLabel
Impaired oxidation of debrisoquine in patients with perhexiline neuropathy
@ast
Impaired oxidation of debrisoquine in patients with perhexiline neuropathy
@en
Impaired oxidation of debrisoquine in patients with perhexiline neuropathy
@nl
P2093
P2860
P3181
P356
P1433
P1476
Impaired oxidation of debrisoquine in patients with perhexiline neuropathy
@en
P2093
P2860
P3181
P356
10.1136/BMJ.284.6312.295
P407
P577
1982-01-30T00:00:00Z